1. A. E. Berbari and G.

Mancia, Cardiorenal Syndrome: Mechanisms, Risk and Treatment, Springer, New

York, NY, USA, 2010.(64)
2. Amaki, T. (2004). Circulating malondialdehyde modified LDL is a biochemical risk marker for
coronary artery disease. Heart, 90(10), 1211–1213.(78)
3. Aparci, M., Kardesoglu, E., Ozmen, N., Ozcan, O., Cebeci, B. S., Cingozbay, B. Y. and Dincturk, M.:
Prognostic significance of ischemia-modified albumin in patients with acute coronary syndrome.
Coron. Artery Dis., 18(5): 367–373 (2007).(43)
4. Apple FS, Quist HE, Otto AP, Mathews WE, Murakami MM. Release characteristics of cardiac
biomarkers and ischemia modified albumin as measured by the albumin cobalt-binding test after a
marathon race. Clin Chem. 2002;48:1097-1100.(18)
5. Bar-Or D, Winkler JV, Vanbenthuysen K, Harris L, Lau E, Hetzel FW. Reduced albumin-cobalt binding
with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a
preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. Am Heart J.
2001;141:985-991.(19)
6. Bar-Or, D., Curtis, G., Rao, N., Bampos, N. and Lau, E.: Characterization of the Co(2＋) and Ni(2＋)
binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a
new assay for myocardial ischemia. Eur. J. Biochem., 268(1): 42–47 (2001).()30
7. Bar-Or, D., Lau, E. and Winkler, J. V.: A novel assay for cobaltalbumin binding and its potential as a
marker for myocardial ischemia-a preliminary report. J. Emerg. Med., 19(4): 311–315 (2000).(28)
8. Bar-Or, D., Winkler, J. V., Vanbenthuysen, K., Harris, L., Lau, E. and Hetzel, F. W.: Reduced
albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal
coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I.
Am. Heart J., 141(6): 985–991 (2001).(29)
9. Berenshtein, E., Mayer, B., Goldberg, C., Kitrossky, N. and Chevion, M.: Patterns of mobilization of
copper and iron following myocardial ischemia: possible predictive criteria for tissue injury. J. Mol.
Cell Cardiol., 29(11): 3025–3034 (1997). (26)
10. Bhagwan N, Ernest M, Rios P, et al. Evolution of human serum albumin cobalt binding assay for the
assessment of myocardial ischemia and myocardial infarction. Clin Chem. 2003;49:581-585
[PubMed].(4)
11. Bhakthavatsala Reddy, C., Cyriac, C., & Desle, H. B. (2014). Role of “Ischemia Modified Albumin”
(IMA) in acute coronary syndromes. Indian Heart Journal, 66(6), 656–662.(20)
12. Chan, B., Dodsworth, N., Woodrow, J., Tucker, A. and Harris, R.: Site-specific N-terminal auto-
degradation of human serum albumin. Eur. J. Biochem., 227(1–2): 524–528 (1995).(22)
13. Chawla R, Navendu G, Rajneesh C, Goyal Shweta. Ischemia Modified Albumin: a novel marker for
acute coronary syndrome. Indian J Clin Biochem. 2006;21:77-82 [PMC free article] [PubMed].(5)
14. Chevion, M., Jiang, Y., Har-El, R., Berenshtein, E., Uretzky, G. and Kitrossky, N.: Copper and iron
are mobilized following myocardial ischemia: possible predictive criteria for tissue injury. Proc. Natl.
Acad. Sci. U.S.A., 90(3): 1102–1106 (1993).()27
15. Christenson, R. H., Duh, S. H., Sanhai, W. R., Wu, A. H., Holtman, V., Painter, P., Branham, E.,
Apple, F. S., Murakami, M. and Morris, D. L.: Characteristics of an Albumin Cobalt Binding Test for
assessment of acute coronary syndrome patients: a multicenter study. Clin. Chem., 47(3): 464–470
(2001).(39)
16. Cobbe, S. M. and Poole-Wilson, P. A.: The time of onset and severity of acidosis in myocardial
ischaemia. J. Mol. Cell Cardiol., 12(8): 745–760 (1980).(25)
17. Collinson, P. O., Gaze, D. C., Bainbridge, K., Morris, F., Morris, B., Price, A. and Goodacre, S.:
Utility of admission cardiac troponin and ``Ischemia Modified Albumin'' measurements for rapid
evaluation and rule out of suspected acute myocardial infarction in the emergency department.
Emerg. Med. J., 23(4): 256–261 (2006).(41)
18. Descamps-Latscha B, Drueke T, Witko-Sarsat V. (2001) Dialysisinduced oxidative stress:biological
aspects, clinical consequences, and therapy. Semin Dial 14, 193–199. (53)
19. Drucke T, Witko-Sarsat V, Massy Z. (2002) Iron therapy, AOPP, and carotid artery IMT in end-stage
renal disease. Circulation 106, 2212–2217.(57)
20. Duseja R, Feldman JA. Missed acute cardiac ischemia in the ED: limitations of diagnostic testing. Am
J Emerg Med. 2004;22:219-225.(6)
21. Dusek, J., St'asek, J., Tichy, M., Bis, J., Gregor, J., Vojacek, J., Masin, V., Polansky, P., Brtko, M.
and Cernohorsky, D.: Prognostic significance of ischemia modified albumin after percutaneous
coronary intervention. Clin. Chim. Acta, 367(1–2): 77–80 (2006).(37)
22. Eftihia S, Panagiota G, Dimitrios T, Kremastinos, Vasilious V. Ischemia modified Albumin: this marker
of ischemia ready for prime time use? Hell J Cardiol. 2008;49:260-266[PubMed].(1)
23. Ehara S, Ueda M, Naruko T, et al.: Elevated levels of oxidized low density lipoprotein show a positive
relationship with the severity of acute coronary syndromes. Circulation 2001, 103:1955–1960.(70)
24. F. Galli, “Protein damage and inflammation in uraemia and dialysis patients,” Nephrology Dialysis
Transplantation, vol. 22, no. 5, pp. v20–v36, 2007.(63)
25. G. Colombo, F. Reggiani, D. Cucchiari et al., “Plasma proteinbound di-tyrosines as biomarkers of
oxidative stress in end stage renal disease patients on maintenance haemodialysis,” BBA Clinical,
vol. 7, pp. 55–63, 2017. (61)
26. Garrido, I. P., Roy, D., Calvino, R., Vazquez-Rodriguez, J. M., Aldama, G., Cosin-Sales, J., Quiles,
J., Gaze, D. C. and Kaski, J. C.: Comparison of ischemia-modified albumin levels in patients
undergoing percutaneous coronary intervention for unstable angina pectoris with versus without
coronary collaterals. Am. J. Cardiol., 93(1): 88–90 (2004).(36)
27. Gaze, D. C. (2009). Ischemia Modified Albumin: A Novel Biomarker for the Detection of Cardiac
Ischemia. Drug Metabolism and Pharmacokinetics, 24(4), 333–341. (45)
28. Goldstein JA, Demetriou BD, Grines CL. (2000) Multiple complex coronary plaques in patients with
acute myocardial infarction. N Engl J Med 343, 915–922.(54)
29. Gryszczyńska, B., Formanowicz, D., Budzyń, M., Wanic-Kossowska, M., Pawliczak, E.,
Formanowicz, P., … Iskra, M. (2017). Advanced Oxidation Protein Products and Carbonylated
Proteins as Biomarkers of Oxidative Stress in Selected Atherosclerosis-Mediated Diseases. BioMed
Research International, 2017, 1–9.(58)
30. H. Mirzaei, B. Baena, C. Barbas, and F. E. Regnier, “Identification of oxidized proteins in rat plasma
using avidin chromatography and tandem mass spectrometry,” Proteomics, vol. 8, no. 7, pp. 1516–
1527, 2008.(65)
31. Hjoiirtshøj Søren, Kristensen Risom, Ravkilde Jan. Diagnostic value of ischemia-modified albumin in
patients with suspected acute coronary syndrome. Am J Emerg Med. 2010;28:170-176.(15)
32. Ho, E., Karimi Galougahi, K., Liu, C.-C., Bhindi, R., & Figtree, G.
A.(2013). Biologicalmarkers of oxidative stress: Applications to cardiovascular research and
practice. Redox Biology, 1(1), 483–491.(48)
33. J. Mikołajczyk-Stecyna, A. Korcz, M. Gabriel, K. Pawlaczyk, G. Oszkinis, and R. Słomski, “Risk factors
in abdominal aortic aneurysm and aortoiliac occlusive disease and differences between them in the
Polish population,” Scientific Reports, vol. 3, article no. 3528, 2013.(59)
34. Kalousova M, Fialova L, Zima T, Malbohan IM. (2002) Advanced oxidation protein products in
pregnancy. Ceska Gynekol 67, 194– 197.(56)
35. Kaneda H, Taguchi J, Ogasawara K. (2002) Increased level of advanced oxidation protein products in
patients with coronary artery disease. Atherosclerosis 162, 221–225.(50)
36. Keating L, Benger JR, Beetham R, et al. The PRIMA study: presentation ischaemia-modified albumin
in the emergency department. Emerg Med J. 2006;23:764-768.(14)
37. L. Selmeci, “Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the
non-enzymatic antioxidant system of the plasma proteome?” Free Radical Research, vol. 45, no. 10,
pp. 1115–1123, 2011.(60)
38. Lee YW, Kim HJ, Cho YH, Shin HB, Choi TY, Lee YK. Application of albumin-adjusted ischemia
modified albumin index as an early screening marker for acute coronary syndrome. Clin Chim Acta.
2007;384:24-27.(12)
39. Leewenburgh C, Hardy MM, Hazen SL. (1997) Reactive nitrogen intermediates promote low density
lipoprotein oxidation in human atherosclerotic intima. J Biol Chem 272, 1433–1436.(49)
40. Levine, R. L.: Ischemia: from acidosis to oxidation. FASEB J., 7(13): 1242–1246 (1993).(24)
41. M. Škvařilová, A. Bulava, D. Stejskal, S. Adamovská, J. Bartek.Icreased level of advanced oxidation
products(AOPP) as a marker of oxidative stress in patients with acute coronary syndrome. Biomed.
Papers 149(1), 83–87 (2005).(51)
42. Madole MB, Bachewar NP, Aiyar CM. Study of oxidants and antioxidants in patients of acute
myocardial infarction. Adv Biomed Res 2015;4:241.(79)
43. Mallinson, T (2010). „Myocardial Infarction”. Focus on First Aid (15): 15(47)
44. Marx, G. and Chevion, M.: Site-specific modification of albumin by free radicals. Reaction with
copper(II) and ascorbate. Biochem. J., 236(2): 397–400 (1986).(31)
45. May Khalil Ismail1 , M. Y. Samera2 , S. K. Abid1: Oxidative stress markers and antioxidant activity in
patients admitted to Intensive Care Unit with acute myocardial infarction. Int J Health Sci
(Qaasim). 2018 Sep-Oct; 12(5): 14–19.(83)
46. McCord, J. M.: Oxygen-derived free radicals in postischemic tissue injury. N. Engl. J. Med., 312(3):
159–163 (1985). (23)
47. Meisinger C, Baumert J, Khuseyinova N, et al.: Plasma oxidized low-density lipoprotein, a strong
predictor for acute coronary heart disease events in apparently healthy, middle-aged men from the
general population. Circulation 2005, 112:651–657(77).
48. Mendis, S., Thygesen, K., Kuulasmaa, K., Giampaoli, S., Mahonen, M., … Ngu Blackett, K.
(2010). World Health Organization definition of myocardial infarction: 2008-09 revision.
International Journal of Epidemiology, 40(1), 139–146.(46)
49. Montagnana M, Lippi G, Guidi GC. New perspectives in the diagnostic approach to acute coronary
syndrome. Recenti Prog Med. 2005;96:171-177.(7)
50. Montagnana M, Lippi G, Guidi GC. New perspectives in the diagnostic approach to acute coronary
syndrome. Recenti Prog Med. 2005;96:171-177.(8)
51. Mothes, E. and Faller, P.: Evidence that the principal CoII-binding site in human serum albumin is
not at the N-terminus: implication on the albumin cobalt binding test for detecting myocardial
ischemia. Biochemistry, 46(8): 2267–2274 (2007).(32)
52. Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 2005;26:33-65.(82)
53. Navab M, Ananthramaiah GM, Reddy ST, et al.: Thematic review series: the pathogenesis of
atherosclerosis: the oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and
HDL. J Lipid Res 2004, 45:993–1007.(67)
54. Nishi K, Itabe H, Uno M, et al.: Oxidized LDL in carotid plaques and plasma associates with plaque
instability. Arterioscler Thromb Vasc Biol 2002, 22:1649–1654.(71)
55. Palinski W, Napoli C: The fetal origins of atherosclerosis: maternal hypercholesterolemia, and
cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming
and postnatal susceptibility to atherogenesis. FASEB J 2002, 16:1348–1360.(69)
56. Peacock F, Morris DL, Anwaruddin S, et al. Meta-analysis of ischemia-modified albumin to rule out
acute coronary syndromes in the emergency department. Am Heart J. 2006;152:253-262.(13)
57. Peacock, F., Morris, D. L., Anwaruddin, S., Christenson, R. H., Collinson, P. O., Goodacre, S. W.,
Januzzi, J. L., Jesse, R. L., Kaski, J. C., Kontos, M. C., Lefevre, G., Mutrie, D., Sinha, M. K.,
Uettwiller-Geiger, D. and Pollack, C. V.: Meta-analysis of ischemia-modified albumin to rule out
acute coronary syndromes in the emergency department. Am. Heart J., 152(2): 253–262 (2006).(44)
58. Quiles, J., Roy, D., Gaze, D., Garrido, I. P., Avanzas, P., Sinha, M. and Kaski, J. C.: Relation of
ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to
duration of balloon-induced myocardial ischemia. Am. J. Cardiol., 92(3): 322–324 (2003).(35)
59. Roy D, Quiles J, Aldama G, et al. Ischemia modified albumin for the assessment of patients
presenting to the emergency department with acute chest pain but normal or nondiagnostic 12-lead
electrocardiograms and negative cardiac troponin T. Int J Cardiol. 2004;97:297-301.(11)
60. Sadler, P. J., Tucker, A. and Viles, J. H.: Involvement of a lysine residue in the N terminal Ni2＋ and
Cu2＋ binding site of serum albumins. Comparison with Co2＋, C＋ and Al3＋. Eur. J. Biochem.,
220(1): 193–200 (1994).(21)
61. Seljelflot I, Aase O, Eid H. (2002) Levels of oxidative stress are associated with C-reactive protein
levels in patients with stable and unstable angina. Europ Heart J 4, 298–306(55)
62. Senes, M., Kazan, N., Coskun, O., Zengi, O., Inan, L. and Yucel, D.: Oxidative and nitrosative stress
in acute ischaemic stroke. Ann. Clin. Biochem., 44(Pt 1): 43–47 (2007).(33)
63. Shaoquing Ju, Juan NI, Jianyou SU, Min PAN, Jianhua Z. Ischemia modified albumin is increased in
patients with unstable angina: a new potential diagnostic biomarker of this acute coronary
syndrome? Science. 2008;39:668-670.(3)
64. Shimada K, Mokuno H, Matsunaga E, et al.: Circulating oxidized low-density lipoprotein is an
independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis
2004, 174:343–347.(74)
65. Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski J-C. Role of ischemia modified albumin a new
biochemical marker of myocardial ischemia, in the early diagnosis of acute coronary syndromes.
Emerg Med J. 2004;21:29-34.(10)
66. Sinha, M. K., Roy, D., Gaze, D. C., Collinson, P. O. and Kaski, J. C.: Role of ``Ischemia modified
albumin'', a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute
coronary syndromes. Emerg. Med. J., 21(1): 29–34 (2004).(40)
67. Sinha, M. K., Vazquez, J. M., Calvino, R., Gaze, D. C., Collinson, P. O. and Kaski, J. C.: Effects of
balloon occlusion during percutaneous coronary intervention on circulating Ischemia Modified
Albumin and transmyocardial lactate extraction. Heart, 92(12): 1852–1853 (2006).(34)
68. Sorescu D, Weiss MD, Lassege B. (2002) Superoxide Production and Expression of Nox Family
Proteins in human atherosclerosis. Circulation 105, 1429–1435.(52)
69. T. Miyata, K. Eckardt, and M. Nangaku, “Transition metals and other forms of oxidative protein
damage in renal disease,” in Studies on Renal Disorders, Humana Press, Totowa, NJ, USA, 2011.(62)
70. The Joint European Society of Cardiology and American College of Cardiology Committee.
Myocardial infarction redefined e a consensus document of the Joint European Society of
Cardiology/American College of Cardiolog.(9)
71. Tsimikas S, Brilakis ES, Miller ER, et al.: Oxidized phospholipids, Lp(a) lipoprotein, and coronary
artery disease. N Engl J Med 2005, 353:46–57.(73)
72. Tsimikas S, Glass C, Steinberg D, Witztum JL: Lipoproteins, lipoprotein oxidation and atherogenesis.
In Molecular Basis of Cardiovascular Disease. A companion to Braunwald’s Heart Disease. Edited by
Chien KR. Philadelphia: WB Saunders; 2004:385–413.(66)
73. Tsimikas S, Witztum JL, Miller ER, et al.: High-dose atorvastatin reduces total plasma levels of
oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with
acute coronary syndromes in the MIRACL trial. Circulation 2004, 110:1406–1412.(75)
74. Tsimikas S, Witztum JL: Measuring circulating oxidized lowdensity lipoprotein to evaluate coronary
risk. Circulation 2001, 103:1930–1932.(68)
75. Tsimikas, S. (2006). Oxidized low-density lipoprotein biomarkers in atherosclerosis. Current
Atherosclerosis Reports, 8(1), 55–61.(72)
76. Vamadevan S, Ajay Doraraj P. Prevalence. Indian J Med Res. 2010;132:561-566 [PMC free article]
[PubMed].(2)
77. Venardos KM, Perkins A, Headrick J, Kaye DM. Myocardial ischemiareperfusion injury, antioxidant
enzyme systems, and selenium: A review. Curr Med Chem 2007;14:1539-49.(80)
78. Wallenfeldt K, Fagerberg B, Wikstrand J: Oxidized lowdensity lipoprotein in plasma is a prognostic
marker of subclinical atherosclerosis development in clinically healthy men. J Intern Med 2004,
256:413–420.(76)
79. Worster, A., Devereaux, P. J., Heels-Ansdell, D., Guyatt, G. H., Opie, J. Mookadam, F. and Hill, S.
A.: Capability of ischemiamodified albumin to predict serious cardiac outcomes in the short term
among patients with potential acute coronary syndrome. CMAJ., 172(13): 1685–1690 (2005).(42)
80. Wu AHB. The ischemia-modified albumin biomarker for myocardial ischemia. MLO Med Lab Obs.
2003;6:36-40.(16)
81. Wu, A. H., Morris, D. L., Fletcher, D. R., Apple, F. S., Christenson, R. H. and Painter, P. C.: Analysis
of the Albumin Cobalt Binding (ACB) test as an adjunct to cardiac troponin I for the early detection
of acute myocardial infarction. Cardiovasc. Toxicol., 1(2): 147–151 (2001).(38)
82. Zapico-Muniz E, Santalo-Bel M, Merce-Muntanola J, Montiel JA, Martinez-Rubio A, Ordonez-Llanos
J. Ischemiamodified albumin during skeletal muscle ischemia. Clin Chem. 2004;50:1063-1065.(17)
83. Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res
2006;70:181-90(81).